Louis Lange Biography and Net Worth

Director of NewAmsterdam Pharma

Dr. Lou Lange has 22 years of experience in academic medicine at Harvard University and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital from 1985 to 1992 and was one of the first academicians in molecular cardiology. He founded CV Therapeutics based on this broad field and served as Chairman, CEO, and Chief Scientific Officer. Dr. Lange is a member of the Board of Trustees at the University of Rochester and a member of BIO Board of Directors. Dr. Lange has been on numerous other public and private boards in both the nonprofit and for-profit arenas. Dr. Lange has a bachelor’s degree from the University of Rochester and earned his MD and PhD in biological chemistry from Harvard University.

What is Louis G. Lange's net worth?: The estimated net worth of Louis G. Lange is at least $296.50 thousand as of March 11th, 2026. Lange owns 10,360 shares of NewAmsterdam Pharma stock worth more than $296,503 as of March 13th. This net worth estimate does not reflect any other investments that Lange may own. Learn More about Louis G. Lange's net worth.
How do I contact Louis G. Lange?: The corporate mailing address for Lange and other NewAmsterdam Pharma executives is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. NewAmsterdam Pharma can also be reached via phone at 352062971 and via email at [email protected]. Learn More on Louis G. Lange's contact information.
Has Louis G. Lange been buying or selling shares of NewAmsterdam Pharma?: In the last ninety days, Louis G. Lange has sold $2,186,260.24 of NewAmsterdam Pharma stock. Most recently, Louis G. Lange sold 44,619 shares of the business's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a transaction totalling $1,357,309.98. Following the completion of the sale, the director now directly owns 10,360 shares of the company's stock, valued at $315,151.20. Learn More on Louis G. Lange's trading history.
Who are NewAmsterdam Pharma's active insiders?: NewAmsterdam Pharma's insider roster includes Juliette Audet (Insider), Michael Davidson (CEO), Johannes Kastelein (Insider), Douglas Kling (COO), Louise Kooij (CAO), Louis Lange (Director), and James Topper (Director). Learn More on NewAmsterdam Pharma's active insiders.
Are insiders buying or selling shares of NewAmsterdam Pharma?: During the last twelve months, NewAmsterdam Pharma insiders bought shares 7 times. They purchased a total of 15,890 shares worth more than $320,789.33. During the last twelve months, insiders at the sold shares 26 times. They sold a total of 1,891,887 shares worth more than $58,221,922.80. The most recent insider tranaction occured on March, 11th when Director Louis G Lange sold 44,619 shares worth more than $1,357,309.98. Insiders at NewAmsterdam Pharma own 20.8% of the company. Learn More about insider trades at NewAmsterdam Pharma.
Information on this page was last updated on 3/11/2026.

Louis G. Lange Insider Trading History at NewAmsterdam Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2026	Sell	44,619	$30.42	$1,357,309.98	10,360
3/6/2026	Sell	28,186	$29.41	$828,950.26
2/13/2024	Buy	5,000	$19.00	$95,000.00	24,878

Louis G. Lange Buying and Selling Activity at NewAmsterdam Pharma

NewAmsterdam Pharma Company Overview

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Today's Range

Now: $28.62

$28.53

$30.74

50 Day Range

MA: $33.10

$28.62

$36.17

2 Week Range

Now: $28.62

$14.06

$42.00

Volume

964,955 shs

Average Volume

867,980 shs

Market Capitalization

$3.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04